Key facts
- DefEYE’s last known valuation is $31.0M (Oct 2025).
- It has raised $12.0M; the latest was Seed Round ($12.0M) in Oct 2025.
- Notable investors include Celularity, ExSight Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for DefEYE
- ·The full record, as it builds
Funding rounds
No funding rounds for DefEYE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DefEYE
Developer of ophthalmic-biologic technology intended for ocular surface repair and surgery. The company's platform offers a portfolio of decellularized human amniotic and placental basement-membrane products, tri-layer and single-layer architectures with preserved natural extracellular matrix structure, multiple sizes and shapes, room-temperature shelf stability, and compatibility with both in-office and surgical applications, enabling eye-care practitioners and healthcare institutions to access regenerative biologic tools for managing complex ocular surface disease, pterygium repair, and other surgical interventions.
- Sector
- Healthcare
- HQ
- FL
- Founded
- 2022
- Website
- defeye.com/
- Ownership
- Privately Held (backing)
DefEYE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DefEYE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DefEYE in its N-PORT filings yet. We sweep new filings monthly.